The increased TGI and augmented CD8+ T cell response was limited to those tumor+HS-5 bearing mice receiving the combination of VLA4 blockade and bispecific antibody treatment and was absent when the mice were dosed with either agent by themselves. Here, CD8A is linked to neoplasm.